The In Vivo Biologic Effect of Interleukin 2 and Interferon Alfa on Natural Immunity in Patients With Head and Neck Cancer

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

1976 • 721 citations

Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

1981 • 703 citations

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

1989 • 383 citations

Reactivity of lymphocytes from normal persons on cultured tumor cells.

1973 • 383 citations

Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

1988 • 200 citations

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

1988 • 159 citations

Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck.

1988 • 156 citations

Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.

1988 • 153 citations

In vivo anti‐tumor activity of combinations of interferon alpha and interleukin‐2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells

1987 • 146 citations

In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.

1988 • 131 citations

Combination Immunotherapy for Cancer:Synergistic Antitumor Interactions of Interleukin-2, Alfa Interferon, and Tumor-Infiltrating Lymphocytes

1988 • 128 citations

Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer

1987 • 123 citations

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.

1987 • 119 citations

Natural Killer Cell Activity and Head and Neck Cancer: A Clinical Assessment<xref ref-type="fn" rid="FN2">2</xref>

1986 • 108 citations

Interaction of recombinant interferons with recombinant interleukin‐2: Differential effects on natural killer cell activity and interleukin‐2‐activated killer cells

1986 • 101 citations

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.

1989 • 96 citations

Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial.

1987 • 87 citations

Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.

1989 • 85 citations

Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients.

1988 • 84 citations

In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.

1988 • 79 citations

Comparison of immune derangements in patients with different malignancies

1980 • 69 citations

Immunobiologic Staging of Patients with Carcinoma of the Head and Neck

1983 • 67 citations

Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.

1989 • 57 citations

Alterations in T-Lymphocyte Subpopulations in Patients With Head and Neck Cancer: Correlations With Prognosis

1987 • 56 citations

The immunology of cancer of the head and neck with particular reference to oral cancer

1982 • 37 citations

Multimodality Therapy and Distant Metastases: The Impact of Natural Killer Cell Activity

1987 • 35 citations

Tumor Immunotherapy by Local Injection of Interleukin 2 and Non-Reactive Lymphocytes

2015 • 34 citations

Immunologic determinants of head and neck cancer response to induction chemotherapy.

1989 • 30 citations

Phase I study of combination therapy with interleukin 2 and beta-interferon in patients with advanced malignancy.

1989 • 30 citations

THE RELATIONSHIP OF CIRCULATING IgA TO CELLULAR IMMUNITY IN HEAD AND NECK CANCER PATIENTS

1988 • 29 citations

Adoptive Immunotherapy for Head and Neck Cancer with Killer Cells Induced by Stimulation with Autologous or Allogeneic Tumour Cells and Recombinant Interleukin-2

1989 • 28 citations

Unique immunobiological aspects of head and neck squamous carcinoma.

1975 • 24 citations

Repetitive weekly cycles of interleukin 2: effect of outpatient treatment with a lower dose of interleukin 2 on non-major histocompatibility complex-restricted killer activity.

1989 • 23 citations

Association of levels of circulating C1q binding macromolecules with induction chemotherapy response in head and neck cancer patients.

1988 • 14 citations

Differential sensitivity of head and neck cancers to non-major histocompatibility-restricted killer cell activity

1990 • 14 citations

Adoptive immunotherapy with interleukin-2 (IL-2) results in diminished IL-2 production by stimulated peripheral blood lymphocytes

1989 • 10 citations